Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Sirolimus combined with oseltamivir and corticosteroid treatment for a puerpera with severe pneumonia caused by 2009 pandemic H1N1: A case report

Lijun Suoa,b,1, Xiaofeng Yub,c,1, Yongfeng Hua,b,c,1, Hongyun Caod,e,1, Xiaohui Zouf, Peiquan Wanga, Tao Xu8, Xiangzhi Zhoug, Yexin Wug, Lili Rend,e,1

ARTICLE INFO

Keywords:
Sirolimus
Oseltamivir
Corticosteroid
Puerpera
Pneumonia
H1N1

ABSTRACT
Severe pneumonia in patients infected with the 2009 pandemic H1N1 (pH1N1) virus was partially attributed to excessive immune response. Anti-virus treatment for these patients was insufficient. Here we reported the therapy effect of sirolimus, an immunosuppressors, combined with oseltamivir and corticosteroid for a puerpera with severe pneumonia caused by pH1N1 virus. This patient has infected with the pH1N1 virus in late pregnancy, and antiviral therapy was not implemented timely. She developed severe pneumonia and ARDS rapidly and need receive a cesarean section on the 39th week after pregnancy. After giving birth to a healthy baby, she received a combination of oseltamivir, sirolimus and corticosteroid, and improved in the following days. Moreover, the cytokines in serum and viral loads in BALF decreased significantly. She recovered without infectious symptoms and was discharged. Sirolimus combined with oseltamivir and corticosteroid is likely responsible for lowering the viral loads, reducing the patient’s cytokine level, and further improving her clinical outcomes. It provides evidence that adjuvant treatment was beneficial to patients with severe pneumonia induced by the pH1N1 virus.

1. Introduction
Pneumonia is the most common complication of pH1N1 infection, which can further develop into aggressive respiratory failure, acute respiratory distress syndrome (ARDS), and fatal outcomes, especially during pregnancy and the early postpartum period [1,2]. “Cytokine storm” induced by hyperactive immune has been reported in patients with severe influenza pH1N1 [3,4]. Although early antiviral therapy with a neuraminidase inhibitor (NAI) is associated with improved outcomes in patients hospitalized with influenza, a significant number of deaths still occurred [5]. Therefore, other therapeutic regimens such as immunoregulation should be considered to decrease morbidity and mortality. It has been reported that sirolimus, an immunosuppressors, combined with oseltamivir and corticosteroid treatment, effectively improved the outcome of patients with severe pH1N1-induced pneumonia and respiratory failure [6]. To our knowledge, this is the

https://doi.org/10.1016/j.bsheal.2021.11.003
Received 5 September 2021; Revised 7 November 2021; Accepted 10 November 2021
Available online xxxx
2590-0536/© 2021 Chinese Medical Association Publishing House. Published by Elsevier BV.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Please cite this article in press as: L Suo et al. Sirolimus combined with oseltamivir and corticosteroid treatment for a puerpera with severe pneumonia caused by 2009 pandemic H1N1: A case report. Biosafety and Health (2021), https://doi.org/10.1016/j.bsheal.2021.11.003
Fig. 1. The oxygenation index variation and the parallel respiratory support treatment, chest X-ray, methylprednisolone, oseltamivir, and sirolimus administration in the puerpera during the therapy process. IMV = invasive mechanical ventilation, INV = intermittent non-invasive ventilation.

Fig. 2. The change of leading infection indicators of the patient from admission to discharge. WBC = white blood cell (normal range: $3.5 \times 10^9$–$9.5 \times 10^9$/L), PCT = procalcitonin (normal range: 0–0.5 ng/ml), L = lymphocyte (normal range: $1.1 \times 10^9$–$3.2 \times 10^9$/L), LDH = lactate dehydrogenase (normal range: $1.09 \times 10^2$–$2.45 \times 10^2$/L).
only clinical trial about sirolimus administration for the patients with
severe pH1N1 infection so far, without using puerpera. Here we
reported a puerpera with severe pH1N1-induced pneumonia recovered
by the sirolimus treatment combined with oseltamivir and
corticosteroid.

2. Case report

A 34-year-old pregnant woman with cough and fever was admitted
to the Obstetric ward at Linzi District People’s Hospital, Shandong Pro-
vince, on Jan 25th, 2016 (Day 1). The patient was pregnant for
35 weeks and four days. She had a dry and itchy nose three days
ago, with a cough but no sputum production. Fever emerged 5 h ago
with the highest temperature of 39.1 °C. In the following four days,
she developed excess sputum, shortness of breath, and tonsil swelling.
Blood tests showed a normal white blood cell (WBC) count
(5.46 × 10⁹/L) but decreased lymphocyte count (0.36 × 10⁹/L)
and increased CRP (60.4 mg/L) level. Arterial blood gas test exhibited
the following results: pH 7.18 (the normal ranges, 7.35–7.45), partial
pressure of carbon dioxide 53 mmHg (the normal ranges,
35–45 mmHg), partial pressure of oxygen 105 mmHg (the normal ranges,
80–100 mmHg) and PO₂/FiO₂ 105 mmHg (the normal ranges,
400–500 mmHg). Though ceftriaxone (2 g/day, iv drip), dexametha-
sone (2 mg/d, iv drip), budesonide (4 mg/d, inh), oxygen therapy,
and other supportive treatments were given, her high fever still progressed. Worst still, Color Doppler Ultrasound showed reduced amni-
otic fluid and poor intrauterine environment in the patient. She
succeeded in the cesarean section surgery and gave an infant in good
condition on Jan 30th (Day 6). The patient was admitted to the Inten-
sive Care Unit (ICU) for her persistent high fever (with a body temper-
ature of 39.1 °C), the requirement of mechanical ventilation for severe
acute respiratory distress syndrome (ARDS). Chest radiograph showed
bilateral pulmonary patchy clouding opacity, and a large amount of
bloody sputum was suctioned by trachea cannula. The patient was
given oseltamivir (150 mg/12 h), broad-spectrum antibiotic (Sulpera-
zone, 3 g/8 h, iv drip and linezolid, 0.6 g/12 h iv drip), antifungal
drugs (voriconazole, 0.2 g/d), methylprednisolone (80 mg/d, iv drip)
and human immunoglobulin (12.5 g/d iv drip) for anti-infection ther-
apy immediately. Subsequently, pH1N1 virus infection was laboratory-
confirmed on a pharyngeal swab using real-time polymerase chain
reaction assay (DAAN Gene, Guangzhou, China) on Day 7. Considering
that pH1N1 virus infection was known to induce cytokine storm and
excessive inflammation, combinations of antiviral and immunomodu-
latory therapies would be beneficial in treating severe influenza pneu-
monia, sirolimus (2 mg/d, nasogastric tube feeding) was added on Day
9. By implementing the combination therapy, the patient’s clinical
manifestation improved gradually, finally recovered, and was dis-
charged on Feb 21st, 2016 (Day 28). Eighteen days later (Day 47),
re-examination showed normal blood indices, arterial blood gas, and
improving chest radiograph.

Oseltamivir was stopped on Day 15; Sirolimus was stopped on Day
22; methylprednisolone was reduced to 4 mg/d before discharge and

---

Fig. 3. Lung computed tomography test of the patient. A) On Day 12, lung computed tomography revealed a large patch of ground-glass opacity. B) On Day 19, it also showed a large patch of ground-glass ambiguity but absorbed partially than before. C) On Day 25, a large patch of ground-glass opacity also existed, but it was allivated compared with the CT scan of the lung on day 19. D) On Day 44, the date of the patient re-examination, lung computed tomography showed patchy and streaky opacity, which improved significantly than that on Day 25.
stopped on Day 44. Also, invasive ventilation weaned off on Day 15, with resolved chest X-ray manifestation indicated by the upward trend of PO2/FiO2 (Fig. 1). Inflammation infection-related indicators, such as body temperature and procalcitonin, were prone to return to an average level (Fig. 2). Besides, Computed tomography (CT) showed persistent absorption of pulmonary inflammation as well (Fig. 3). Furthermore, serum cytokines including IL-6, IL-10, IL-15, IL-21, INF-γ, and MIP-3a decreased after antiviral therapy, though some increased again on Day 8. Therefore, sirolimus was added on Day 9, IL-6, IL-10, IL-12, IL-15, IL-17, IL-13, IL-21, IL-27, INF-γ, TNF-α, and MIP-3a in serum were reduced gradually to become regular with the combined oseltamivir and sirolimus therapy (Fig. 4).

Hypokalemia, diarrhea, transient elevation of serum triglycerides, hypercholesterolemia, and hyperlipemia are the common side-effects of sirolimus. While during the two weeks treatment, only transient elevation of lactate dehydrogenase was observed in this patient but rapidly returned to normal after sirolimus withdrawal. Secondary infection of bacteria was investigated by repeated bacterial culture of sputum, blood, and bronchoalveolar lavage fluid (BALF) sample from this patient, but no pathogenic strain was isolated. At the same time, metagenomic sequencing of BALF and blood samples showed Pseudomonadaceae (PAE) sequences. The reads amount variation of PAE and influenza virus was the same during the treatment. Both could not be detected in BALF when the patient was discharged (on Days 15 and 21) but re-emerged on Day 44, which might be associated with sirolimus's immunosuppressive effect. Besides, Paramyxoviridae, adenoviridae or nidovirale, retroviridae, etc. were also detected in BALF. But both of them had no significance after clinical evaluation, which included symptoms, signs, imaging tests and laboratory detection, etc. Sequence amount of PAE in blood was not affected by a combined therapy (Fig. 5). Therefore, more pathogens could be detected by metagenomic sequencing than traditional tests, but clinical evaluation should determine their pathogenicity.

3. Discussion

Pregnant women were considered at high risk for influenza virus infection and influenza-associated death, especially in the third trimester of pregnancy. Therefore, antiviral therapy with oseltamivir within 48 h from symptom onset could benefit the clinical efficacy [2,7]. However, oseltamivir often is administrated beyond the recommended window in clinical practice. This case involved a pregnant woman with severe pH1N1 infection and was rescued successfully by sirolimus along with oseltamivir and corticosteroid. As far as we know, this is the first case report on adjuvant sirolimus treatment for a pregnant woman with pH1N1 virus-induced severe pneumonia.

Sirolimus, also known as rapamycin, is an inhibitor of kinase mTOR (mammalian target of rapamycin) which plays a critical role in virus replication and regulating host innate and adaptive immune system [8]. A prospective clinical study indicated that adjuvant therapy with sirolimus, oseltamivir, and corticosteroids effectively treated pH1N1 patients with ARDS and respiratory failure [6]. Our case also demonstrated the process of a pregnant woman with severe pneumonia recovered by sirolimus, oseltamivir, and corticosteroid administration, indicating that sirolimus was beneficial to the patients with severe
viral pneumonia. Besides, we revealed that delayed oseltamivir plus sirolimus treatment protects mice against lethal pH1N1 infection by attenuating severe lung injury. Furthermore, the mechanism inhibited NLRP3 inflammasome activation and inflammatory response cell infiltration [9]. However, Alsuwaidi et al [10] claimed that sirolimus treatment exacerbates respiratory function by increasing viral titer and worsening lung inflammation. But in their study, oseltamivir was not used. Therefore, the adverse outcome was regarded as viral replication due to immunosuppression.

Abnormal “cytokine storm” plays a critical role in influenza-induced severe pneumonia. High levels of pro-inflammatory cytokines have been reported in patients with severe pH1N1 virus infection. These cytokines may be induced by the viral infection (primary cytokines), such as type I and III interferons, or immune response (secondary cytokines), including INF-γ, IL-10, etc. [11]. Corticosteroids have been suggested as an anti-inflammatory treatment for early ALI/ARDS induced by influenza infection. However, other studies showed that high doses or sustained corticosteroids might be harmful to these patients by increasing viral load and secondary bacterial infection [12,13]. In our case, methylprednisolone was given after cesarean section (Day 6), the dose was reduced gradually from 80 to 0 mg/d. Oseltamivir was also administrated immediately after operation. Cytokines in serum were progressively reduced to an average level with the combined therapy. Sirolimus inhibits cytokines production is associated with the mTOR signaling pathway, which has a vital role in regulating pro- and anti-inflammatory responses in innate immune cells. Blocking mTOR or its downstream signaling molecules impairs the production of type I IFN from plasmacytoid DCs [14]. Inhibiting mTOR also suppressed TNF-α and IL-6 in serum, alleviated lung injury, and improved mouse survival with LPS induced ALI [15–17]. Further research was needed to elucidate the mechanism of sirolimus inhibiting cytokine expression in patients with severe pneumonia caused by pH1N1 infection.

Influenza virus infection increases the risk of second bacterial infection by causing impaired immune responses in the lung [18–20]. In our case, no bacteria were detected by traditional bacteria or fungi culture, but metagenomic sequencing identified PAE sequence in blood and BALF. Because the patient in our case had been discharged without infection-related symptoms when the sequencing results were made, no antibiotic was specially used to target the PAE. Still, it could be covered by the broad-spectrum antibiotics empirically given to this patient. Consequently, the PAE sequence number in BALF was gradually decreased to zero, while its percentage showed relatively small variation in blood, which we evaluated as no clinical significance.

**Ethics statement**

The ethics committee approved this case study of Linzi District People’s Hospital, Zibo City, Shandong Province, China, and written informed consent was obtained from the patient to publish this case report.
Fig. 4. Serum cytokines variation of the patient during her hospitalization. A) The variation of INF-\(\gamma\), IL-21, IL-15, IL-12p70, IL-17A, and IL-27 in serum. B) The variation of IL-10, IL-6, TNF-\(\alpha\), IL-13 and MIP-3\(\alpha\) in serum. The number in the ellipse and rectangle meant the day that oseltamivir and sirolimus were given, respectively.
Fig. 5. The sequence variation assigned to bacteria and viruses in BALF and blood during the patient’s therapy process detected by metagenomic sequencing. The yellow bar represents the influenza H1N1 virus; the blue bar presents P. aeruginosa.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Author contributions

Lili Ren, Bo Liu and Bin Cao: Conceptualization, Methodology, Writing - Review & Editing. Lijun Suo, Xiaofeng Yu, Yongfeng Hu and Hongyun Cao: Data Curation, Writing - Original Draft. XiaoHui Zou: Formal Analysis. Peiquan Wang, Tao Xu, Xiangzhi Zhou and Yexin Wu: Investigation, Writing - Review & Editing.

Acknowledgements

This study was supported by the Taishan Scholars Program of Shandong Province (tsqn202103196), Shandong Medical and Health Technology Development Project (2018WS006), and the Key Research and Development Project ZiBo City (2018kj060040, 2016kj060025).

References

[1] R.H. Beigi, V.C. Pillai, R. Venkataramanan, S.N. Caritis, Oselamivir for the treatment of H1N1 influenza during pregnancy, Clin. Pharmacol. Ther. 98 (2015) 403-405. https://doi.org/10.1002/cpt.179.
[2] Richard H. Beigi, Prevention and management of influenza in pregnancy, Obstet Gynecol Clin North Am. 41 (4) (2014) 535-546. https://doi.org/10.1016/j.ogc.2014.08.002.
[3] D.S. Hui, N. Lee, P.K. Chan, J.H. Beigel, The role of adjuvant immunomodulatory agents-ent for-treatment of severe influenza, Antiviral Res. 150 (2018) 202-216. https://doi.org/10.1016/j.antiviral.2018.01.002.
[4] C.J. Murray, A.D. Lopez, B. Chin, D. Feehan, K.H. Hill, Estimation of potential global pame-dic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis, Lancet 368 (9554) (2006) 2211-2218. https://doi.org/10.1016/S0140-6736(06)69595-4.
[5] P.K. Chan, R. Villar, J. Beigel, The battle over mTOR: an emerging theatre in host p-a-thogen immunity, PLoS Pathog. 8 (2012),https://doi.org/10.1371/journal.ppat.1002894.
[6] S. Martin, B. Saha, J.L. Riley, The battle over mTOR: an emerging theatre in host p-a-thogen immunity, PLoS Pathog. 8 (2012),https://doi.org/10.1371/journal.ppat.1002894.
Q. Li, C. Shan, H.J. Yu, A.D. Yang, Emodin alleviated pulmonary inflammation in rats with LPS-induced acute lung injury through inhibiting the mTOR/HIF-1α/VEGF signaling pathway, Inflamm Res 69 (2020) 365–373, https://doi.org/10.1007/s00011-020-01331-3.

E.Y. Klein, B. Monteforte, A. Gupta, W. Jiang, L. May, Y.H. Hsieh, A. Dugas, The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis, Influenza Other Respir. Viruses. 10 (5) (2016) 394–403, https://doi.org/10.1111/irv.2016.10.issue-5.10.1111/irv.12398.

H. Ishikawa, T. Fukui, S. Ino, H. Sasaki, N. Awano, C. Kohda, K. Tanaka, Influenza virus infection causes neutrophil dysfunction through reduced G-CSF production and an increased risk of secondary bacteria infection in the lung, Virology 499 (2016) 23–29, https://doi.org/10.1016/j.virology.2016.08.025.

E. Azoulay, L. Russell, A. Van de Louw, V. Metaxa, P. Bauer, P. Povoa, J.G. Montero, I.M. Loeches, S. Mehta, K. Puxty, et al, Diagnosis of severe respiratory infections in immunocompromised patients, Intensive Care Med. 46 (2) (2020) 298–314, https://doi.org/10.1007/s00134-019-05906-5.